| __timestamp | Takeda Pharmaceutical Company Limited | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 612613000000 | 91733000 |
| Thursday, January 1, 2015 | 650773000000 | 87644000 |
| Friday, January 1, 2016 | 619061000000 | 92365000 |
| Sunday, January 1, 2017 | 628106000000 | 85656000 |
| Monday, January 1, 2018 | 717599000000 | 88196000 |
| Tuesday, January 1, 2019 | 964737000000 | 89971000 |
| Wednesday, January 1, 2020 | 875663000000 | 93413000 |
| Friday, January 1, 2021 | 886361000000 | 91355000 |
| Saturday, January 1, 2022 | 997309000000 | 113676000 |
| Sunday, January 1, 2023 | 1053819000000 | 198366000 |
| Monday, January 1, 2024 | 1053819000000 | 218935000 |
Cracking the code
In the competitive world of pharmaceuticals, understanding spending patterns is crucial. Takeda Pharmaceutical Company Limited, a Japanese multinational, and Taro Pharmaceutical Industries Ltd., an Israeli company, offer a fascinating study in contrasts. Over the past decade, Takeda's Selling, General, and Administrative (SG&A) expenses have surged by approximately 72%, reflecting its aggressive expansion and strategic acquisitions. In 2023, Takeda's SG&A expenses reached a staggering 1.05 trillion yen, a testament to its global ambitions.
Conversely, Taro's SG&A expenses have remained relatively stable, with a modest increase of around 140% since 2014. This stability highlights Taro's focus on maintaining operational efficiency while navigating the complex pharmaceutical landscape. As we look to the future, these spending patterns may offer insights into each company's strategic priorities and market positioning.
Johnson & Johnson vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Takeda Pharmaceutical Company Limited and argenx SE
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs BeiGene, Ltd. Trends and Insights
Breaking Down SG&A Expenses: Takeda Pharmaceutical Company Limited vs Axsome Therapeutics, Inc.
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs Halozyme Therapeutics, Inc.
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Veracyte, Inc. Trends and Insights
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs Celldex Therapeutics, Inc.
argenx SE or Taro Pharmaceutical Industries Ltd.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Alkermes plc vs Taro Pharmaceutical Industries Ltd.
Cost Management Insights: SG&A Expenses for Protagonist Therapeutics, Inc. and Taro Pharmaceutical Industries Ltd.
Operational Costs Compared: SG&A Analysis of Taro Pharmaceutical Industries Ltd. and Novavax, Inc.
Taro Pharmaceutical Industries Ltd. or BioCryst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?